Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 2
2020 11
2021 8
2022 4
2023 3
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer.
Bulle A, Liu P, Seehra K, Bansod S, Chen Y, Zahra K, Somani V, Khawar IA, Chen HP, Dodhiawala PB, Li L, Geng Y, Mo CK, Mahsl J, Ding L, Govindan R, Davies S, Mudd J, Hawkins WG, Fields RC, DeNardo DG, Knoerzer D, Held JM, Grierson PM, Wang-Gillam A, Ruzinova MB, Lim KH. Bulle A, et al. Nat Commun. 2024 Mar 20;15(1):2503. doi: 10.1038/s41467-024-46811-w. Nat Commun. 2024. PMID: 38509064 Free PMC article.
Hormonal modulation of ESR1 mutant metastasis.
Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, Fernandez NM, Grimm SL, Hilsenbeck SG, Liu D, Xu J, Alaniz A, Li S, Mills GB, Janku F, Kittler R, Zhang XH, Coarfa C, Foulds CE, Symmans WF, Andò S, Fuqua SAW. Gu G, et al. Oncogene. 2021 Feb;40(5):997-1011. doi: 10.1038/s41388-020-01563-x. Epub 2020 Dec 15. Oncogene. 2021. PMID: 33323970 Free PMC article.
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.
Chen A, Kim BJ, Mitra A, Vollert CT, Lei JT, Fandino D, Anurag M, Holt MV, Gou X, Pilcher JB, Goetz MP, Northfelt DW, Hilsenbeck SG, Marshall CG, Hyer ML, Papp R, Yin SY, De Angelis C, Schiff R, Fuqua SAW, Ma CX, Foulds CE, Ellis MJ. Chen A, et al. Mol Cancer Ther. 2024 Oct 1;23(10):1494-1510. doi: 10.1158/1535-7163.MCT-23-0564. Mol Cancer Ther. 2024. PMID: 38781103 Free PMC article.
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.
Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, Evans KW, Li D, Rubinstein L, Welm A, Dean DA 2nd, Srivastava A, Grover JW, Ha MJ, Chen H, Huang X, Varadarajan K, Wang J, Roth JA, Welm B, Govinden R, Ding L, Kaochar S, Mitsiades N, Carvajal-Carmona L, Herylyn M, Davies MA, Shapiro GI, Fields R, Trevino JG, Harrell JC; NCI PDXNet Consortium; Doroshow JH, Chuang JH, Moscow JA. Meric-Bernstam F, et al. Mol Cancer Ther. 2024 Jul 2;23(7):924-938. doi: 10.1158/1535-7163.MCT-23-0471. Mol Cancer Ther. 2024. PMID: 38641411 Free PMC article.
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.
Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH; PDXNET Consortium; EurOPDX Consortium. Woo XY, et al. Nat Genet. 2021 Jan;53(1):86-99. doi: 10.1038/s41588-020-00750-6. Epub 2021 Jan 7. Nat Genet. 2021. PMID: 33414553 Free PMC article.
Cancer proteogenomics: current impact and future prospects.
Mani DR, Krug K, Zhang B, Satpathy S, Clauser KR, Ding L, Ellis M, Gillette MA, Carr SA. Mani DR, et al. Nat Rev Cancer. 2022 May;22(5):298-313. doi: 10.1038/s41568-022-00446-5. Epub 2022 Mar 2. Nat Rev Cancer. 2022. PMID: 35236940 Review.
High-Contrast Detection of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery.
Hernandez Vargas S, AghaAmiri S, Ghosh SC, Luciano MP, Borbon LC, Ear PH, Howe JR, Bailey-Lundberg JM, Simonek GD, Halperin DM, Tran Cao HS, Ikoma N, Schnermann MJ, Azhdarinia A. Hernandez Vargas S, et al. Mol Pharm. 2022 Nov 7;19(11):4241-4253. doi: 10.1021/acs.molpharmaceut.2c00583. Epub 2022 Sep 29. Mol Pharm. 2022. PMID: 36174110 Free PMC article.
32 results